| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-01-28 | Bone Therapeutics (Belgium) | €7.7 million | Series D financing round | Nausicaa Ventures (Belgium) BAMS Angels Fund I (Belgium) Life Science Research Partners (Belgium) Société Régionale d\'Investissement de Wallonie (SRIW) (Belgium) Sambrinvest (Belgium) | Bone diseases | Series D financing round |
| 2013-01-28 | Avillion (UK) | undisclosed | series A financing round | Abingworth (UK) Clarus Ventures (USA - CA) | Series A financing round | |
| 2013-01-25 | Epigenomics (Germany - USA) | € 4,976,099 | capital increase by way of a rights issue | Diagnostic - Cancer - Oncology | Capital increase | |
| 2013-01-25 | Cytox (UK) | £3.5 million (€4 million) | Diagnostic | Fundraising | ||
| 2013-01-23 | Gene Signal (Switzerland) | financing round | Ophtalmological diseases - Metabolic diseases - Rare diseases - Cancer - Oncology | Establishment of a new subsidiary in the EU | ||
| 2013-01-22 | Lophius Biosciences (Germany) | € 4 million | VRD GmbH (Germany) WIC GmbH (Germany) S-Refit (Germany) HighTech Gründerfonds (HTGF) (Germany) Bayern Kapital (Germany) two Business Angels | Diagnostic | Fundraising | |
| 2013-01-16 | Pharming (The Netherlands) | €16.35 million | convertible bond financing | syndicate of existing specialised and institutional investors led by Kingsbrook Opportunities Master Fund LP | Rare diseases | Private placement |
| 2013-01-15 | DBV Technologies (France) INRA (France) | €600.000 | grant | ANR - French National Research Agency (France) | Infectious diseases | Grant |
| 2013-01-11 | Biotec Pharmacon (Norway) | NOK 40 million (€ 5.45 million) | private placement | |||
| 2013-01-10 | Galapagos (Belgium) | €2.7 million | grant | Flemish agency for Innovation by Science and Technology (IWT) (Belgium) | Infectious diseases | Grant |
| 2013-01-09 | Spinomix (Switzerland) | $ 3 million (€2.3 million) | series A financing round | Debiopharm Group™ (Switzerland) existing investors undisclosed private US investor group | Diagnostic | Fundraising |
| 2013-01-07 | Prosonix (UK) | £1.3 million | grant | Biomedical Catalyst Fund (UK) | Respiratory diseases | Grant |
| 2013-01-07 | Drug Response Dx (Germany) | undisclosed | financing round | High-Tech Gründerfonds (Germany) Qiagen (The Netherlands) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Fundraising |
| 2013-01-07 | ISA Pharmaceuticals (The Netherlands) | € 8 million | financing round | Infectious diseases | Fundraising | |
| 2013-01-04 | Theradiag (France) | €8.6 million | IPO | institutional investors public |
Diagnostic - Autoimmune diseases - Inflammatory diseases- Infectious diseases - Cancer -Oncology | IPO |
| 2013-01-03 | Amakem (Belgium) | € 1.4 million | grant | Flemish Agency for Innovation by Science and Technology (IWT) (Belgium) | Autoimmune diseases – Inflammatory diseases - Immunological diseases - Digestive diseases | Grant |
| 2012-12-20 | Tigenix (Belgium) | € 6.7 million | private placement | Autoimmune diseases- Immunological diseases - Digestive diseases | Private placement | |
| 2012-12-19 | NeRRe Therapeutics (UK) | £11.5 million (€14.1 million) | series A financing round | Novo A/S (Denmark) Advent Venture Partners (UK) GSK (UK) |
Fundraising | |
| 2012-12-18 | Karo Bio (Sweden) | MSEK 32.6 million (€3.7 million) | rights issue | Private placement | ||
| 2012-12-17 | Galapagos (Belgium) | €1,336,886.63 | capital increase through employee warrant exercises | employees | Capital increase |
